PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents growing 13.68% while TRVN's declined -10.68%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of TRVN's -10.68%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of TRVN's -7.94%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
≥ 1.5x TRVN's -2.78%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
1.25-1.5x TRVN's -67.65%. Martin Whitman might worry about unproductive asset buildup.
-8.29%
Below half of TRVN's 2.42%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of TRVN's -7.24%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Less than half of TRVN's 31.13%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
50-75% of TRVN's 3.13%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Below half of TRVN's -69.66%. Michael Burry suspects a big gap in pre-sales traction.
-2.34%
Less than half of TRVN's -26.22%. David Dodd sees fewer expansions in other current obligations.
-12.65%
50-75% of TRVN's -18.42%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Above 1.5x TRVN's -2.72%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Similar yoy to TRVN's -13.70%. Walter Schloss sees parallel expansions in total liabilities.
5.56%
Above 1.5x TRVN's 0.63%. Michael Burry suspects heavy new equity expansion or dilution.
-2.30%
Similar yoy to TRVN's -2.22%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half TRVN's -5.76%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half TRVN's -7.24%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Above 1.5x TRVN's -2.15%. Michael Burry sees a major jump. Investigate leverage rationale.
-14.00%
Less than half of TRVN's 11.33%. David Dodd sees better deleveraging or stronger cash buildup than competitor.